MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2016 International Congress

    Improving drug discovery using brain oscillations as biomarkers of Parkinson’s disease

    B. Pouyatos, S.J. Perry, D.E. Grigoriadis, R. Maury, C. Bouyssières, C. Roucard, V. Duveau, Y. Roche (La Tronche, France)

    Objective: The aim of this study was to assess the use of cortical oscillations as translational biomarkers for drug development for the motor symptoms of…
  • 2016 International Congress

    The potential therapeutic effect of intranasal administration of stem cells in rotenone model of Parkinson’s disease in mice

    M. El-Gamal, M. Salama, M. Sobh, M. Emam, A. Abdalla, A. Lotfy, D. Sabry, M. El-Qotb, M. Sobh (Mansoura, Egypt)

    Objective: In this study we assessed the potential beneficial effect of intranasal administration of mesenchymal stem cells (MSCs) to rotenone model of PD in C57bl/6…
  • 2016 International Congress

    Utility of IgGs subtypes in hemolytic anemia prevention and treatment maintenance in patients treated with continous infusion of apomorphine

    P. Sanchez-Lozano, E. Suarez, R. Ribacoba (Gijon, Spain)

    Objective: The objetive of our study is to assess the utility of the subtypes IgG direct Coombs test (DCT) in maintenance apomorphine treatment without risk…
  • 2016 International Congress

    Expiratory muscle training for the impaired loudness of speech in Parkinson’s disease: An open-label study

    S. Tomita, T. Oeda, A. Umemura, M. Kohsaka, K. Park, K. Yamamoto, H. Sugiyama, H. Sawada (Kyoto, Japan)

    Objective: To investigate the efficacy of EMT for the impaired loudness of speech in patients with PD, we conducted an open-label pilot trial of EMT.…
  • 2016 International Congress

    Does physical exercise influence the cognitive domains that predict dementia in Parkinson’s disease?

    C.R.A. Silveira, E.A. Roy, B.N. Intzandt, Q.J. Almeida (Waterloo, ON, Canada)

    Objective: This study aimed to investigate the effects of aerobic and goal-based exercise on memory, language, and visuospatial functions in cognitively normal and impaired individuals…
  • 2016 International Congress

    Body position during sleep in patients with Parkinson’s disease (PD): A sensor-based analysis

    J. Sringean, P. Taechalertpaisarn, C. Thanawattano, R. Bhidayasiri (Nonthaburi, Thailand)

    Objective: To identify the body position during sleep in PD patients in comparison to their spouses by using multisite wearable inertial sensors. Background: Nocturnal hypokinesia…
  • 2016 International Congress

    The Parkinson progression marker initiative (PPMI) – Developing a comprehensive longitudinal biomarker dataset

    Parkinson Progression Marker Initiative (New Haven, CT, USA)

    Objective: The goal of the Parkinson Progression Marker Initiative (PPMI) is to identify clinical, imaging and biospecimen biomarkers of PD progression to provide tools for…
  • 2016 International Congress

    Cognitive behavioural thrapy and adiunctive physical therapy for functional movement disorders

    R. Erro, M. Tinazzi, C. Dallocchio (London, United Kingdom)

    Objective: To test the feasibility and efficacy of Cognitive Behavioural Therapy (CBT) and Adjunctive Physical Therapy (APA) APA in Functional Movement Disorders (FMD). Background: Functional…
  • 2016 International Congress

    KINECT 3: A randomized, double-blind, placebo-controlled phase 3 trial of valbenazine (NBI-98854) for tardive dyskinesia

    S.A. Factor, R.A. Hauser, S. Siegert, G.S. Liang, C.F. O'Brien (Atlanta, GA, USA)

    Objective: To assess the efficacy, safety and tolerability of valbenazine (NBI-98854) for Tardive Dyskinesia (TD). Background: Tardive dyskinesia (TD) is a persistent and often disabling…
  • 2016 International Congress

    Risk factors for premature withdraw from the LS-1 PD study

    J.Y. Fang, S. Luo, M. Huang, R.B. Dewey, R. Hauser, G. Chen (Nashville, TN, USA)

    Objective: To identify risk factors for premature withdrawal from a large, multi-center Parkinson's disease clinical trial of possible neuroprotection. Background: Premature withdrawal (PW) of subjects…
  • « Previous Page
  • 1
  • …
  • 17
  • 18
  • 19
  • 20
  • 21
  • …
  • 207
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • An atypical and interesting feature of Parkinson´s disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • #23812 (not found)
  • Approaching Health Care Shaped by Generational Expectations (The AGE Study): Generational Perspective Related to Time
  • Application of the “5-2-1” Screening Criteria in Advanced Parkinson’s Disease Patients Treated with Levodopa-Carbidopa Intestinal Gel: Interim Analysis from the DUOGLOBE Study
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Effect of Ketone Ester Supplementation on Motor and Non-Motor symptoms in Parkinson's Disease
  • An atypical and interesting feature of Parkinson´s disease
  • Patients with Essential Tremor Live Longer than their Relatives
  • DaTscan in clinical evaluation of Multiple System Atrophy
  • Decision-making process for opicapone’s bedtime regimen
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley